The Virology Market is on a robust growth trajectory, with global sales projected to rise from USD 2,333.2 million in 2025 to USD 3,808.9 million by 2035, at a CAGR of 5.0%. The industry witnessed a revenue of USD 2,249.5 million in 2024, reflecting a Y-o-Y growth of 3.3%. The market’s expansion is fueled by the increasing prevalence of viral diseases, technological advancements in diagnostics, and heightened demand for antiviral therapies and vaccines.
Explore trends before investing – request a sample report today!
Rising Demand for Diagnostics and Advanced Therapies
Diagnostic tests dominate the virology market, accounting for 46.4% of the 2025 value share. Rapid antigen tests, PCR, and ELISA techniques are increasingly adopted to identify viral infections early, guide treatment strategies, and monitor disease progression. Growing awareness of viral illnesses, coupled with the emergence of pandemics like COVID-19, has accelerated demand for precise and rapid diagnostic tools.
Simultaneously, antiviral therapies, interferons, and mRNA vaccines present significant growth opportunities. mRNA technology enables rapid vaccine development for emerging infectious diseases, providing scalability, adaptability, and cost-efficiency. These advancements empower manufacturers to address multiple viral strains and variants, strengthening their competitive position in established and emerging markets.
Strategic Collaborations Fuel Innovation
Strategic collaborations between pharmaceutical companies and research institutes are accelerating market growth. Partnerships enhance drug development expertise, facilitate clinical research innovation, and enable access to high-performance laboratories and advanced screening platforms. For example, in February 2023, GSK plc invested USD 1.5 million in the University of Alberta’s Li Ka Shing Institute of Virology to drive breakthroughs in antivirals and vaccines.
Research institutes are also prioritizing the development of versatile diagnostic tools, such as Columbia University’s VirCapSeq approved in 2022 for systemic and respiratory infections. These innovations expand access to early detection, promote personalized medicine, and improve global healthcare outcomes.
Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates
Regional Insights: APAC, Europe, USA, and Saudi Arabia
In the United States, virology market growth is driven by strong private and pharmaceutical investments, leading to advancements in antiviral therapies, vaccines, and diagnostics. The U.S. is projected to maintain a 6.6% CAGR through 2035, retaining its dominant North American market share of 84.7%.
China anticipates a CAGR of 4.2%, fueled by emerging and re-emerging viral infections, increasing demand for vaccines, antiviral drugs, and rapid diagnostic solutions. Urbanization and population density further amplify viral transmission risks, creating opportunities for healthcare innovation.
Germany benefits from government funding and public-private partnerships to develop vaccines and antiviral treatments. In July 2023, the German Federal Ministry of Education and Research supported five non-profit organizations focused on accessible vaccine R&D, reinforcing market growth.
Across APAC, countries like South Korea are projected to grow at 5.2% CAGR, while India and Japan register steady growth rates of 3.8% and 4.6%, respectively. GCC countries, including Saudi Arabia, show moderate but stable expansion at 2.4%, supported by rising healthcare investments.
Hospitals and End-Users Lead Adoption
Hospitals are the leading end-users of virology solutions, accounting for 58.4% of the market in 2025. Equipped with advanced diagnostics and skilled professionals, hospitals manage complex viral infections, oversee antiviral treatments, and act as hubs for clinical innovation. While clinics, laboratories, and diagnostic centers play essential roles, hospitals dominate due to patient volume, comprehensive services, and specialized care capabilities.
Competitive Landscape and Market Drivers
Tier 1 companies, such as Gilead Sciences, AbbVie, and GSK plc, control 61.6% of the market, offering extensive portfolios and broad geographic reach. Mid-tier companies (Tier 2) and specialized suppliers (Tier 3) contribute to market diversity and innovation. Key recent developments include Gilead Sciences’ 2023 virology R&D updates and Shionogi & Co., Ltd.’s Phase 1 COVID-19 drug trial in Japan.
Despite promising growth, challenges persist. High development and production costs for vaccines and antiviral therapies hinder accessibility, particularly in low- and middle-income countries, potentially slowing overall adoption.
Buy Report Now – Click Here to Purchase the Report:
https://www.futuremarketinsights.com/checkout/1150
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: [email protected]
Website: https://www.futuremarketinsights.com
